OTTMUSG00000016588 Inhibitors
Chemical inhibitors of CDKs can affect the function of various proteins involved in the regulation of the cell cycle. Among these proteins is OTTMUSP00000016588, which is implicated in the intricate process of cell division and proliferation. Palbociclib, a selective chemical inhibitor, targets CDK4 and CDK6, crucial kinases in the transition from the G1 phase to the S phase of the cell cycle. By inhibiting these kinases, Palbociclib can arrest the cell cycle, impacting the function of OTTMUSP00000016588, which is supposed to act during this critical phase. Similarly, Ribociclib exerts its effect on the same kinases, leading to a halt in cell cycle progression and an indirect impairment of OTTMUSP00000016588 function. Milciclib, while it inhibits a broader range of kinases, still affects the cell cycle in a manner that can disrupt the activity of OTTMUSP00000016588.
Other inhibitors, such as Alsterpaullone, Roscovitine, Olomoucine, Purvalanol A, Indirubin-3'-monoxime, Dinaciclib, and Flavopiridol, though they may have different specificities for various CDKs, converge on a common pathway of cell cycle regulation that involves OTTMUSP00000016588. For instance, Alsterpaullone's inhibition of CDK1, CDK2, and CDK5, or Roscovitine's targeting of CDK1, CDK2, CDK7, and CDK9, all result in an interruption of the cell cycle at different checkpoints. This interruption is significant because it impedes the phosphorylation events necessary for cell cycle progression, events in which OTTMUSP00000016588 is known to participate. Dinaciclib's robust inhibition of CDK1, CDK2, CDK5, and CDK9 has a similar effect, leading to the suppression of the phosphorylation that would normally be mediated by OTTMUSP00000016588 during the cell cycle. Flavopiridol's broad-spectrum inhibition of CDKs also results in cell cycle arrest, further indicating how the activity of OTTMUSP00000016588 is deeply integrated with the proper functioning of CDK-dependent processes. Through the blockade of these kinases, these chemical inhibitors can modulate the cell cycle in a way that affects the function of OTTMUSP00000016588, showcasing the interconnected nature of cell cycle regulation and protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. OTTMUSG00000016588 is known to be part of the cell cycle regulation process, and by inhibiting CDK4/6, Palbociclib leads to cell cycle arrest, thereby inhibiting the function of proteins involved in cell cycle progression, including OTTMUSG00000016588. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor, specifically inhibiting CDK1, CDK2, and CDK5. Since OTTMUSG00000016588 has a role in cell cycle regulation, inhibition of these kinases by Alsterpaullone results in a blockade of cell cycle progression, thus inhibiting the function of OTTMUSG00000016588. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a potent inhibitor of CDKs, including CDK1, CDK2, CDK7, and CDK9. As OTTMUSG00000016588 is involved in the cell cycle, Roscovitine's inhibition of these kinases impedes cell cycle progression, which is necessary for the functional activity of OTTMUSG00000016588. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, notably CDK1, CDK2, and CDK5. The inhibition of these kinases by Olomoucine disrupts the cell cycle, which is crucial for the activity of OTTMUSG00000016588, thus functionally inhibiting the protein. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, particularly CDK1, CDK2, and CDK4. OTTMUSG00000016588, which plays a role in cell cycle regulation, is functionally inhibited by the suppression of these kinases, as it leads to cell cycle arrest at specific checkpoints. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is an inhibitor of CDKs, including CDK1, CDK2, and CDK5. By inhibiting these kinases, it prevents the cell cycle progression, thereby inhibiting the function of OTTMUSG00000016588, which is implicated in the regulation of the cell cycle. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4 and CDK6, kinases involved in the G1-S phase transition of the cell cycle. The inhibition by Ribociclib results in cell cycle arrest, thereby functionally inhibiting OTTMUSG00000016588, which is involved in cell cycle control. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a strong inhibitor of CDK1, CDK2, CDK5, and CDK9. Its action on these kinases halts cell cycle progression, thus functionally inhibiting OTTMUSG00000016588 by preventing the phosphorylation events it mediates during the cell cycle. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib inhibits various CDKs as well as other kinases, but its action on CDKs directly impacts cell cycle progression. This inhibition functionally disables the activity of OTTMUSG00000016588 by blocking the cell cycle events in which it is known to participate. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a pan-CDK inhibitor that targets multiple CDKs involved in cell cycle regulation. The inhibition of these pathways by Flavopiridol leads to cell cycle arrest, effectively inhibiting the function of OTTMUSG00000016588, which is involved in cell cycle progression. | ||||||